245 related articles for article (PubMed ID: 28109099)
1. [Effect of Hugan Qingzhi tablets on AMPK pathway activation and NF-κB-p65 protein expression in the liver of rats with nonalcoholic fatty liver disease].
Yao XR; Xia F; Tang WJ; Zhou BJ
Nan Fang Yi Ke Da Xue Xue Bao; 2017 Jan; 37(1):56-62. PubMed ID: 28109099
[TBL] [Abstract][Full Text] [Related]
2. [Effect of Fuzi Lizhong decoction in reducing liver injury of rats with non-alcoholic fatty liver via activating AMPK and suppressing NF-κBp65 pathway].
Yang JY; Shi ZH; Ma W; Tao DQ; Liu S; Chen L; Zhou XL
Zhongguo Zhong Yao Za Zhi; 2018 Aug; 43(15):3176-3183. PubMed ID: 30200715
[TBL] [Abstract][Full Text] [Related]
3. Hugan Qingzhi medication ameliorates hepatic steatosis by activating AMPK and PPARα pathways in L02 cells and HepG2 cells.
Yin J; Luo Y; Deng H; Qin S; Tang W; Zeng L; Zhou B
J Ethnopharmacol; 2014 May; 154(1):229-39. PubMed ID: 24735863
[TBL] [Abstract][Full Text] [Related]
4. Isobaric tags for relative and absolute quantitation (iTRAQ)-based proteomics for the investigation of the effect of Hugan Qingzhi on non-alcoholic fatty liver disease in rats.
Yao X; Xia F; Tang W; Xiao C; Yang M; Zhou B
J Ethnopharmacol; 2018 Feb; 212():208-215. PubMed ID: 29031784
[TBL] [Abstract][Full Text] [Related]
5. Hugan Qingzhi tablets attenuates endoplasmic reticulum stress in nonalcoholic fatty liver disease rats by regulating PERK and ATF6 pathways.
Yang M; Yao X; Xia F; Xiang S; Tang W; Zhou B
BMC Complement Med Ther; 2024 Jan; 24(1):36. PubMed ID: 38216941
[TBL] [Abstract][Full Text] [Related]
6. Kangtaizhi Granule Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats and HepG2 Cells via AMPK/mTOR Signaling Pathway.
Zhang J; Du H; Shen M; Zhao Z; Ye X
J Immunol Res; 2020; 2020():3413186. PubMed ID: 32884949
[TBL] [Abstract][Full Text] [Related]
7. Chinese herbal medicine mixture 919 syrup alleviates nonalcoholic fatty liver disease in rats by inhibiting the NF-κB pathway.
Chen M; Xing J; Pan D; Peng X; Gao P
Biomed Pharmacother; 2020 Aug; 128():110286. PubMed ID: 32521450
[TBL] [Abstract][Full Text] [Related]
8. [Effect of diosgenin on mTOR/FASN/HIF-1α/VEGFA expression in rats with non-alcoholic fatty liver disease].
Yin GL; Liang HY; Liang PP; Feng YN; Chen SW; Liu XY; Pan WC; Zhang FX
Zhongguo Zhong Yao Za Zhi; 2023 Apr; 48(7):1760-1769. PubMed ID: 37282950
[TBL] [Abstract][Full Text] [Related]
9. [Effects of sera of rats fed with
Yang M; Chen Z; Xiao C; Tang W; Zhou B
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Nov; 38(11):1277-1287. PubMed ID: 30514673
[TBL] [Abstract][Full Text] [Related]
10. JianPi-QingHua formula attenuates nonalcoholic fatty liver disease by regulating the AMPK/SIRT1/NF-κB pathway in high-fat-diet-fed C57BL/6 mice.
Tian J; Cai M; Jin S; Chen Q; Xu J; Guo Q; Yan Z; Han X; Lu H
Pharm Biol; 2023 Dec; 61(1):647-656. PubMed ID: 37038833
[TBL] [Abstract][Full Text] [Related]
11. [Intervention of Catalpol on High-fat Diet Induced Nonalcoholic Fatty Liver Disease in Mice].
Tian X; Xiong Q; Chen L; Wen JR; Ru Q
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Dec; 41(6):746-755. PubMed ID: 31907123
[No Abstract] [Full Text] [Related]
12. [Effect of Nrf2 and related factors on the progression of nonalcoholic steatohepatitis].
Cai YQ; Zhang LZ; Wang DJ; Chen FM; Chen ZY; Zhu KY; Li JS; Yan MX
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2014 Sep; 30(5):465-70. PubMed ID: 25571645
[TBL] [Abstract][Full Text] [Related]
13. Hugan Qingzhi Exerts Anti-Inflammatory Effects in a Rat Model of Nonalcoholic Fatty Liver Disease.
Tang W; Zeng L; Yin J; Yao Y; Feng L; Yao X; Sun X; Zhou B
Evid Based Complement Alternat Med; 2015; 2015():810369. PubMed ID: 26146507
[TBL] [Abstract][Full Text] [Related]
14. Modulation of the Gut Microbiota in Rats by Hugan Qingzhi Tablets during the Treatment of High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease.
Tang W; Yao X; Xia F; Yang M; Chen Z; Zhou B; Liu Q
Oxid Med Cell Longev; 2018; 2018():7261619. PubMed ID: 30671174
[TBL] [Abstract][Full Text] [Related]
15. [Effects of soothing liver and invigorating spleen recipes on NF-kappaB signal pathway related genes and proteins in primary hepatocytes of rats with NASH].
Yang QH; Xu YJ; Feng GF; Yang XS; Han L; Zhang YP; Wang H
Zhong Yao Cai; 2013 Sep; 36(9):1469-76. PubMed ID: 24620695
[TBL] [Abstract][Full Text] [Related]
16. Berberine inhibits liver damage in rats with non-alcoholic fatty liver disease by regulating TLR4/MyD88/NF-κB pathway.
Wang L; Jia Z; Wang B; Zhang B
Turk J Gastroenterol; 2020 Dec; 31(12):902-909. PubMed ID: 33626003
[TBL] [Abstract][Full Text] [Related]
17. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease.
Yang JM; Sun Y; Wang M; Zhang XL; Zhang SJ; Gao YS; Chen L; Wu MY; Zhou L; Zhou YM; Wang Y; Zheng FJ; Li YH
World J Gastroenterol; 2019 Sep; 25(34):5105-5119. PubMed ID: 31558860
[TBL] [Abstract][Full Text] [Related]
18. Daming capsule, a hypolipidaemic drug, lowers blood lipids by activating the AMPK signalling pathway.
Bian Y; Li X; Li X; Ju J; Liang H; Hu X; Dong L; Wang N; Li J; Zhang Y; Yang B
Biomed Pharmacother; 2019 Sep; 117():109176. PubMed ID: 31387185
[TBL] [Abstract][Full Text] [Related]
19. Green tea polyphenols ameliorate non-alcoholic fatty liver disease through upregulating AMPK activation in high fat fed Zucker fatty rats.
Tan Y; Kim J; Cheng J; Ong M; Lao WG; Jin XL; Lin YG; Xiao L; Zhu XQ; Qu XQ
World J Gastroenterol; 2017 Jun; 23(21):3805-3814. PubMed ID: 28638220
[TBL] [Abstract][Full Text] [Related]
20. [Effect of Qingzhi soft capsule on blood lipid level and pathology of the fatty liver in hyperlipidemic rats].
Tong L; Chen YY; Guo YL
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jan; 28(1):73-5. PubMed ID: 18227032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
